Statin use in patients with hormone receptor-positive metastatic breast cancer treated with everolimus and exemestane.

ABSTRACT:

Background

We analyzed the effect of statins in patients with hormone receptor-positive (HR+) metastatic breast cancer treated with everolimus + exemestane (EverX).

Materials and methods

We conducted a nationwide retrospective cohort study using the National Health Insurance database with patients who received EverX for metastatic breast cancer between 2011 and 2019.

Results

Of 224,948 patients diagnosed with breast cancer, 1749 patients who received EverX for at least 30 days were included. Among them, 500 (28.6%) patients were found to take statins with EverX treatment (statin group), and the median duration of this combination was 5.36 months. The median time to treatment duration (TTD) for EverX and the overall survival (OS) were significantly higher in the statin

SUBMITTER: Lee K 

PROVIDER: S-EPMC10028110 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature